4/A: Processa Pharma Director Retracts Erroneous SEC Filing

Processa Pharmaceuticals' Director and President of R&D, David Young, filed an amended Form 4 to retract a previously filed statement of beneficial ownership due to an error.

Summary

• David Young, a Director and President of Research & Development at Processa Pharmaceuticals, Inc. (PCSA), filed a Form 4/A amendment.
• The purpose of this amendment is to retract a prior Form 4 that was filed in error on July 28, 2025.
• The original erroneous filing pertained to a transaction dated July 24, 2025.
• Following this retraction, David Young's beneficial ownership of Common Stock is reported as: 217,332 shares held directly, 30,985 shares held indirectly by Young-Plaisance Revocable Trust, 10,786 shares held indirectly by Family Entities, and 18,544 shares held indirectly by CorLyst, LLC.

Sentiment

Score: 5

Explanation: The filing is a neutral administrative correction of a previous error, not indicative of positive or negative company performance or significant operational changes.

Positives

• The prompt correction of an administrative error ensures the accuracy of public records regarding insider beneficial ownership.

Negatives

• The initial filing of an erroneous Form 4 indicates a lapse in administrative accuracy, requiring a subsequent correction.

Risks

• Potential for administrative errors in SEC filings, which could lead to temporary inaccuracies in public disclosures of insider holdings.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Management Comments

• "Amendment filed to retract the prior Form 4, which was filed in error."

Industry Context

Form 4 filings are standard regulatory disclosures for insiders reporting changes in beneficial ownership. While retractions (Form 4/A) are less common, they occur to correct administrative errors and maintain the accuracy of public records, which is crucial for transparency in the financial markets.

Stakeholder Impact

• Shareholders: Ensures accurate and transparent reporting of insider beneficial ownership, which is vital for informed investment decisions.
• Regulatory Authorities: Demonstrates compliance with SEC reporting requirements by correcting previously filed erroneous information.

Key Dates

Recommendation

This filing is an administrative correction of a previously filed Form 4, retracting an erroneous report. It does not provide new information regarding the company's financial performance, strategic direction, or operational outlook that would warrant a change in investment recommendation. The correction ensures accuracy in insider ownership disclosures, which is a standard regulatory compliance matter.

Keywords

Processa Pharmaceuticals, PCSA, Form 4/A, SEC filing, beneficial ownership, insider holdings, retraction, amendment, David Young, corporate governance